Concept Life Sciences appoints Philip Payne as Chief Commercial Officer
News Oct 24, 2017
Concept Life Sciences announced it has appointed Philip Payne as Chief Commercial Officer, to support the group’s continued growth. Philip completes Concept’s leadership team, following the appointment in August of John Handley as COO.
Philip will work with Concept’s executive team and board to drive the group’s commercial strategy, leading the business development function and helping to guide the next stage of the Company’s growth. He will be responsible for managing the sales team, including identification of new service areas, geographies and markets, supporting the broadening of Concept’s reach into Europe and the US.
Philip has 27 years’ experience in managing the integration of business development in an international environment, and has gained cross-sector expertise through roles in pharma and biotech discovery as well as analytical and development services. He joins Concept from Aptuit, where he held various roles, including Vice President of Sales, and was responsible for the global business development team and strategic accounts. Prior to joining Aptuit he was Business Development Director Europe and Asia for Sterile Technologies at Catalent Pharma Solutions, and Pharmaceutical Business Development Director with Reading Scientific Services Ltd.
Michael Fort, Executive Chairman, Concept Life Sciences, said: “Philip’s experience in managing multidisciplinary, international teams across a range of industries will be a great asset as Concept’s rapid rate of expansion continues. Following on from John’s appointment as COO, Concept now has an extremely strong leadership team. We are delighted to welcome Philip to the group.”
Philip Payne, Chief Commercial Officer, Concept Life Sciences, said: “I am excited to join Concept at this pivotal stage in the growth of the Company, and look forward to working with the team to meet the group’s commercial and strategic objectives.”
Advanced Prostate Cancer: EMA Approves Abiraterone Combined With Hormone Therapy as First-line TreatmentNews
The prostate cancer drug abiraterone has been approved by the European Medicines Agency in combination with standard hormone therapy for use as a first-line treatment for advanced prostate cancer.READ MORE
Diabetes Drug Could Be Re-purposed to Help End Transplant RejectionNews
A diabetes drug currently undergoing development could be repurposed to help end transplant rejection, without the side-effects of current immunosuppressive drugs.READ MORE
Study Shows Cancer Patients Are Choosing Less Severe Side Effects Over Treatment EfficacyNews
When choosing their preferred treatment, people with chronic lymphocytic leukemia (CLL) place the highest value on medicines that deliver the longest progression-free survival, but are willing to swap some drug efficacy for a reduced risk of serious adverse events according to a new study.READ MORE